215 related articles for article (PubMed ID: 19524477)
41. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
Pietz K; Hagell P; Odin P
J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
[TBL] [Abstract][Full Text] [Related]
42. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
43. [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
Rovers JM; Dautzenberg PL; ter Bruggen JP
Tijdschr Gerontol Geriatr; 2006 Jul; 37(3):117-20. PubMed ID: 16886519
[TBL] [Abstract][Full Text] [Related]
44. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
Jansen EN; van Laar T
Ned Tijdschr Geneeskd; 1990 May; 134(18):889-91. PubMed ID: 2345577
[No Abstract] [Full Text] [Related]
45. Future delivery systems for apomorphine in patients with Parkinson's disease.
van Laar T; Van der Geest R; Danhof M
Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
[No Abstract] [Full Text] [Related]
46. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
Goetz CG; Wuu J; Curgian L; Leurgans S
Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144
[TBL] [Abstract][Full Text] [Related]
47. Avoiding mental changes and falls in older Parkinson's patients.
Paulson GW; Schafer K; Hallum B
Geriatrics; 1986 Aug; 41(8):59-62, 67. PubMed ID: 3732809
[TBL] [Abstract][Full Text] [Related]
48. [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
Merello M; Leiguarda R
Medicina (B Aires); 1995; 55(1):5-10. PubMed ID: 7565037
[TBL] [Abstract][Full Text] [Related]
49. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease.
Meral H; Aydemir T; Ozer F; Ozturk O; Ozben S; Erol C; Cetin S; Hanoglu L; Ozkayran T; Yilsen M
Clin Neurol Neurosurg; 2007 Dec; 109(10):862-7. PubMed ID: 17913346
[TBL] [Abstract][Full Text] [Related]
50. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Gancher ST; Woodward WR; Nutt JG
Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
[TBL] [Abstract][Full Text] [Related]
51. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
52. Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease.
Hirayama M; Nakamura T; Watanabe H; Uchida K; Hama T; Hara T; Niimi Y; Ito M; Ohno K; Sobue G
Parkinsonism Relat Disord; 2011 Jan; 17(1):46-9. PubMed ID: 21106430
[TBL] [Abstract][Full Text] [Related]
53. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
Drapier S; Vérin M
Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine.
Sigurdardóttir GR; Nilsson C; Odin P; Grabowski M
Acta Neurol Scand; 2001 Aug; 104(2):92-6. PubMed ID: 11493225
[TBL] [Abstract][Full Text] [Related]
55. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
Fernandez HH; Okun MS; Rodriguez RL; Malaty IA; Romrell J; Sun A; Wu SS; Pillarisetty S; Nyathappa A; Eisenschenk S
Int J Neurosci; 2009; 119(12):2196-205. PubMed ID: 19916848
[TBL] [Abstract][Full Text] [Related]
56. Features associated with the development of hallucinations in Parkinson's disease.
Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
[TBL] [Abstract][Full Text] [Related]
57. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years.
Goetz CG; Stebbins GT; Ouyang B
Mov Disord; 2011 Oct; 26(12):2196-200. PubMed ID: 21755536
[TBL] [Abstract][Full Text] [Related]
58. Visual hallucinations and associated factors in Chinese patients with Parkinson's disease: roles of RBD and visual pathway deficit.
Wang G; Wan Y; Wang Y; Xiao Q; Liu J; Ma JF; Wang XJ; Zhou HY; Tan YY; Cheng Q; Chen SD
Parkinsonism Relat Disord; 2010 Dec; 16(10):695-6. PubMed ID: 20833097
[No Abstract] [Full Text] [Related]
59. Excessive daytime somnolence in Parkinson's disease. Follow-up after 1 year of treatment.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Vanacore N; Meco G
Neurol Sci; 2003 Oct; 24(3):178-9. PubMed ID: 14598075
[TBL] [Abstract][Full Text] [Related]
60. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect.
Martinez-Martin P; Reddy P; Antonini A; Henriksen T; Katzenschlager R; Odin P; Todorova A; Naidu Y; Tluk S; Chandiramani C; Martin A; Chaudhuri KR
J Parkinsons Dis; 2011; 1(2):197-203. PubMed ID: 23934921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
